Sintilimab and Ipilimumab Show Promise in First-line Therapy for Advanced Biliary Tract Cancers
The combination of sintilimab and ipilimumab is being evaluated as a first-line therapy for unresectable and metastatic biliary tract cancers, addressing unmet needs in current treatment regimens.